<DOC>
	<DOCNO>NCT00991172</DOCNO>
	<brief_summary>This phase 2 , randomize , double-blind , parallel-group , single dose study evaluate safety efficacy 2 dose level REGN475 compare placebo patient sciatic pain . Enrollment approximately 50 patient 3 treatment arm expect 35 US site , total enrollment approximately 150 patient . Patients receive 1 injection skin either active placebo REGN475 , follow 10 visit 12 week .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Subcutaneously Administered REGN475 ( SAR164877 ) Patients With Sciatic Pain</brief_title>
	<detailed_description />
	<mesh_term>Sciatica</mesh_term>
	<criteria>1 . Pain present least 2 week , last 16 week prior screen visit . 2 . A confirmed diagnosis sciatica screen visit . 3 . Weight le 120 kg 1 . ï»¿Back surgery within 6 month prior screen visit 2 . Neurological deficit ( muscle weakness and/or reflex loss ; loss bowel bladder function ) cause include sciatica 3 . Other condition may confound interpretation study , carpal tunnel syndrome , MS , rheumatoid arthritis , spinal stenosis , etc . 4 . Allergy doxycycline relate compound 5 . Women pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>sciatica</keyword>
	<keyword>sciatic pain</keyword>
	<keyword>pain</keyword>
	<keyword>back pain</keyword>
</DOC>